Adaptimmune is a leader in TCR T-cell therapy, focused on developing novel cancer immunotherapy products. We utilize the bodyâs own machinery â the T-cell â to target and destroy cancer cells by increasing the affinity of naturally occurring T-cell receptors (TCRs). We have developed a proprietary T-cell receptor platform that enables us to identify cancer targets, find and genetically engineer T-cell receptors, or TCRs, and produce TCR therapeutic candidates called SPEAR (Specific Peptide Enhanced Affinity Receptor) T-cells that recognize these targets on cancer cells. We engineer a patientâs own T-cells to express our SPEAR TCRs to target and potentially destroy tumors. Source
No articles found.
Addus HomeCare is a comprehensive provider of home and community based services, w...
Addus HomeCare is a comprehensive provider of h...
Cardiovascular Systems, Inc., based in St. Paul, Minn., is a medical device compan...
Cardiovascular Systems, Inc., based in St. Paul...
Our strategy is to be known as âthe prostate cancer companyâ. We aspire to be ...
Our strategy is to be known as âthe prostate ...
Opiant is a specialty pharmaceutical company developing medicines for addiction an...
Opiant is a specialty pharmaceutical company de...
miRagen Therapeutics, Inc., is a clinical stage biopharmaceutical company discover...
miRagen Therapeutics, Inc., is a clinical stage...
BioCryst Pharmaceuticals discovers novel, oral small-molecule medicines that treat...
BioCryst Pharmaceuticals discovers novel, oral ...
Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company focus...
Incyte Corporation is a Wilmington, Delaware-ba...
Join the National Investor Network and get the latest information with your interests in mind.